La cadena de opciones muestra datos clave de las opciones de acciones de Cardiol Therapeutics a varios precios de ejercicio y fechas de vencimiento. Los operadores utilizan esta información para analizar posibles operaciones y evaluar el sentimiento del mercado para Cardiol Therapeutics..

Cardiol Therapeutics (NASDAQ:CRDL) Bolsa, Cadena de Opciones

Cardiol Therapeutics

Cardiol Therapeutics Inc is a clinical-stage life sciences company focused on the research and clinical development of anti-inflammatory and anti-fibrotic therapies for the treatment of heart diseases. The company's main product candidate, CardiolRx, is a pharmaceutically manufactured oral cannabidiol formulation that is being clinically developed for use in heart diseases. Cardiol has received Investigational New Drug Application authorization from the United States Food and Drug Administration to conduct clinical studies to evaluate the efficacy and safety of CardiolRx in two diseases affecting the heart which are a Phase II multi-national trial, the ARCHER trial, in acute myocarditis; and a Phase II multi-center open-label pilot study in recurrent pericarditis.

Cardiol Therapeutics Inc. - Class A Common Shares

Cardiol Therapeutics Inc

JP Morgan maintains Celestica (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CLS#NYSE">CLS</a>) with a Overweight and lowers the price target from $166 to $105.

News

Price Target

Analyst Ratings

JP Morgan Maintains Overweight on Celestica, Lowers Price Target to $105

WIIM

Kosmos Energy shares are trading higher after the company announced the first LNG cargo shipment at the Greater Tortue Ahmeyim project.

JP Morgan analyst Samik Chatterjee maintains CDW (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CDW#NASDAQ">CDW</a>) with a Neutral and lowers the price target from $222 to $175.

JP Morgan Maintains Neutral on CDW, Lowers Price Target to $175

Keefe, Bruyette &amp; Woods analyst Catherine Mealor maintains Pinnacle Finl Partners (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PNFP#NASDAQ">PNFP</a>) with a Market Perform and lowers the price target from $130 to $115.

PNFP

Keefe, Bruyette & Woods Maintains Market Perform on Pinnacle Finl Partners, Lowers Price Target to $115

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our <a href="https://www.benzinga.com/analyst-stock-ratings">analyst ratings page</a>.
<ul>
<li>Longbow Research analyst David Macgregor initiated coverage on Twin Disc, Incorporated (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TWIN#NASDAQ">TWIN</a>) with a Buy rating and announced a price target of $12. Twin Disc shares closed at $6.66 on Wednesday. <a href="https://www.benzinga.com/quote/TWIN/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Rosenblatt analyst Blair Abernethy initiated coverage on RedCloud Holdings plc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RCT#NASDAQ">RCT</a>) with a Buy rating and announced a price target of $5. RedCloud shares closed at $1.71 on Wednesday. <a href="https://www.benzinga.com/quote/RCT/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Wells Fargo analyst Eva Fortea Verdejo initiated coverage on Bicara Therapeutics Inc.&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BCAX#NASDAQ">BCAX</a>) with an Underweight rating and announced a price target of&nbsp;$8. Bicara Therapeutics shares closed at $11.76 on Wednesday. <a href="https://www.benzinga.com/quote/AFRM/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Wells Fargo initiated coverage on Relay Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RLAY#NASDAQ">RLAY</a>) with an Equal-Weight rating and announced a price target of&nbsp;$4. Relay Therapeutics shares closed at $2.61 on Wednesday. <a href="https://www.benzinga.com/quote/AFRM/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>BTIG analyst Sam Eiber initiated coverage on Evolus, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EOLS#NASDAQ">EOLS</a>) with a Buy rating and announced a price target of $21. Evolus shares closed at $10.11 on Wednesday.  <a href="https://www.benzinga.com/quote/MSFT/analyst-ratings">See how other analysts view this stock.</a></li>
</ul>
Considering buying TWIN stock? Here&#8217;s what analysts think: 
<figure class="wp-block-image size-large is-resized"><img loading="lazy" decoding="async" width="1024" height="593" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/17074938/image-19-1024x593.png" alt="" class="wp-image-876433" style="width:571px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/17074938/image-19-1024x593.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/17074938/image-19-300x174.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/17074938/image-19-768x445.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/17074938/image-19.png 1117w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
Read This Next: 
<ul>
<li><a href="https://www.benzinga.com/news/earnings/25/04/44857276/netflix-unitedhealth-group-and-3-stocks-to-watch-heading-into-thursday">Netflix, UnitedHealth Group And 3 Stocks To Watch Heading Into Thursday</a> </li>
</ul>
Photo via Shutterstock

Initiation

Pre-Market Outlook

Markets

Trading Ideas

AMKR

BCAX

EOLS

RLAY

TWIN

This Twin Disc Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Thursday

JP Morgan analyst Samik Chatterjee maintains Calix (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CALX#NYSE">CALX</a>) with a Neutral and lowers the price target from $45 to $34.

CALX

JP Morgan Maintains Neutral on Calix, Lowers Price Target to $34

JP Morgan analyst Samik Chatterjee maintains Arista Networks (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ANET#NYSE">ANET</a>) with a Overweight and lowers the price target from $140 to $110.

ANET

JP Morgan Maintains Overweight on Arista Networks, Lowers Price Target to $110

Macro Economic Events

Economics

Federal Reserve

S&P 500 Futures Calm After Fed's Williams Reportedly Says On Fox Business; Monetary Policy Is Well Positioned, Doesn't See Need To Change Rates Any Time Soon, Tariffs Will Drive Up Inflation This Year And Lower Growth

Keefe, Bruyette &amp; Woods analyst Damon Delmonte maintains Nicolet Bankshares (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NIC#NYSE">NIC</a>) with a Market Perform and raises the price target from $115 to $118.

Keefe, Bruyette & Woods Maintains Market Perform on Nicolet Bankshares, Raises Price Target to $118

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our <a href="https://www.benzinga.com/analyst-stock-ratings">analyst ratings page</a>.
<ul>
<li>Citigroup cut Generac Holdings Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GNRC#NYSE">GNRC</a>) price target from $162 to $138. Citigroup analyst Vikram Bagri upgraded the stock from Neutral to Buy. Generac shares closed at $110.65 on Wednesday. See how other analysts <a href="https://www.benzinga.com/quote/GNRC/analyst-ratings">view this stock</a>.</li>
<li>Chardan Capital slashed the price target for Adverum Biotechnologies, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADVM#NASDAQ">ADVM</a>) from $40 to $33. Chardan Capital analyst Daniil Gataulin maintained a Buy rating. Adverum Biotechnologies shares closed at $2.98 on Wednesday. See how other analysts<a href="https://www.benzinga.com/quote/ADVM/analyst-ratings"> view this stock</a>.</li>
<li>Rosenblatt cut Coinbase Global, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/COIN#NASDAQ">COIN</a>) price target from $305 to $290. Rosenblatt analyst Chris Brendler maintained a Buy rating. Coinbase shares closed at $172.21 on Wednesday. See how other analysts <a href="https://www.benzinga.com/quote/COIN/analyst-ratings">view this stock</a>.</li>
<li>Evercore ISI Group slashed the price target for Prologis, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PLD#NYSE">PLD</a>) from $111 to $106. Evercore ISI Group analyst Steve Sakwa maintained an In-Line rating. Prologis shares closed at $100.29 on Wednesday. <a href="https://www.benzinga.com/quote/PLD/analyst-ratings">See how other analysts view this stock.</a></li>
<li>B of A Securities raised the price target for The Progressive Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PGR#NYSE">PGR</a>) from $289 to $297. B of A Securities analyst Joshua Shanker maintained a Neutral rating. Progressive shares closed at $275.13 on Wednesday. <a href="https://www.benzinga.com/quote/PGR/analyst-ratings">See how other analysts view this stock.</a></li>
<li>BMO Capital slashed Novo Nordisk A/S (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVO#NYSE">NVO</a>) price target from $105 to $64. BMO Capital analyst Evan David Seigerman downgraded the stock from Outperform to Market Perform. Novo Nordisk shares settled at $62.88 on Wednesday. <a href="https://www.benzinga.com/quote/NVO/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>HC Wainwright &amp; Co increased Oculis Holding AG (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OCS#NASDAQ">OCS</a>) price target from $29 to $32. HC Wainwright &amp; Co. analyst Yi Chen maintained a Buy rating. Oculis Holding shares closed at $18.02 on Wednesday. <a href="https://www.benzinga.com/quote/OCS/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Scotiabank raised Intuit Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INTU#NASDAQ">INTU</a>) price target from $600 to $700. Scotiabank analyst Allan Verkhovski upgraded the stock from Sector Perform to Sector Outperform. Intuit shares closed at $588.08 on Wednesday.  <a href="https://www.benzinga.com/quote/INTU/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Canaccord Genuity raised the price target for ServiceTitan, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TTAN#NASDAQ">TTAN</a>) from $120 to $130. Canaccord Genuity analyst David Hynes maintained a Buy rating. ServiceTitan shares settled at $117.66 on Wednesday. <a href="https://www.benzinga.com/quote/TTAN/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Keefe, Bruyette &amp; Woods slashed Walker &amp; Dunlop, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WD#NYSE">WD</a>) price target from $105 to $95. Keefe, Bruyette &amp; Woods analyst Jade Rahmani maintained an Outperform rating. Walker &amp; Dunlop shares closed at $73.65 on Wednesday. <a href="https://www.benzinga.com/quote/WD/analyst-ratings">See how other analysts view this stock</a>.</li>
</ul>
Considering buying INTU stock? Here&#8217;s what analysts think: 
<figure class="wp-block-image size-large is-resized"><img loading="lazy" decoding="async" width="1024" height="604" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/17084542/image-21-1024x604.png" alt="" class="wp-image-876630" style="width:565px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/17084542/image-21-1024x604.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/17084542/image-21-300x177.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/17084542/image-21-768x453.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/17084542/image-21.png 1088w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
Read This Next: 
<ul>
<li><a href="https://www.benzinga.com/news/earnings/25/04/44857276/netflix-unitedhealth-group-and-3-stocks-to-watch-heading-into-thursday">Netflix, UnitedHealth Group And 3 Stocks To Watch Heading Into Thursday</a> </li>
</ul>
Photo via Shutterstock

ADVM

COIN

GNRC

INTU

TTAN

Intuit To Rally Around 19%? Here Are 10 Top Analyst Forecasts For Thursday

Empowering Companies to Meet Rising Global Demand for Circular, Transparent, and Efficient Plastics
NEW YORK, NY / <a href="https://www.accessnewswire.com/">ACCESS Newswire</a> / April 17, 2025 / SMX (Security Matters) PLC (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SMX#NASDAQ">SMX</a>)(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SMXWW#NASDAQ">SMXWW</a>), a pioneer in digitizing physical objects for a circular economy, announces a strategic collaboration with Aegis Packaging, a Singapore-based leader in high-barrier coatings for flexible plastic packaging. This alliance merges SMX's invisible molecular marking and blockchain-based platform with Aegis Packaging's O₂X&#x2122; coating technology offering a seamless way to enhance the recyclability and verifiability of plastic packaging

SMXWW

SMX Announces Strategic Collaboration With Aegis Packaging To Meet Rising Global Demand For Circular, Transparent, And Efficient Plastics

Keefe, Bruyette &amp; Woods analyst Christopher Mcgratty maintains Fulton Financial (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FULT#NASDAQ">FULT</a>) with a Market Perform and lowers the price target from $24 to $21.

FULT

Keefe, Bruyette & Woods Maintains Market Perform on Fulton Financial, Lowers Price Target to $21

JP Morgan analyst Samik Chatterjee maintains Amphenol (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/APH#NYSE">APH</a>) with a Overweight and lowers the price target from $90 to $85.

JP Morgan Maintains Overweight on Amphenol, Lowers Price Target to $85

Evotec shares are trading higher. The company reported FY24 financial results.

Better Choice Company, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BTTR#NYSE">BTTR</a>) ("Better Choice" or the "Company"), a pet health and wellness company, today announced that its Board of Directors has reinstated its stock repurchase program and increased authorization up to $6.5 million of its outstanding shares of common stock, until December 31, 2025. The Company repurchased 102,405 common shares at an average price of $1.9869 per share under the previous $5 million stock repurchase program, which expired on December 31, 2024.
Michael Young, Chairman of Better Choice, commented, "After repurchasing 102,405 common shares under our previous repurchase program in 2024, it is in the best interest of our shareholders to reinstate this program and increase the authorized amount up to $6.5 million as we strongly believe our equity to be undervalued."

Buybacks

BTTR

Better Choice Company Has Reinstated Its Stock Repurchase Program And Increased Authorization Up To $6.5M Of Its Outstanding Shares Of Common Stock, Until December 31, 2025

LBRT

Liberty Energy shares are trading higher after the company reported better-than-expected Q1 revenue results.

Keefe, Bruyette &amp; Woods analyst Brady Gailey maintains First Horizon (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FHN#NYSE">FHN</a>) with a Market Perform and lowers the price target from $24 to $22.

Keefe, Bruyette & Woods Maintains Market Perform on First Horizon, Lowers Price Target to $22

Small Cap Consumer Research analyst Eric Beder reiterates Betterware de Mexico SAPI (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BWMX#NYSE">BWMX</a>) with a Buy and maintains $22.5 price target.

Reiteration

BWMX

Small Cap Consumer Research Reiterates Buy on Betterware de Mexico SAPI, Maintains $22.5 Price Target

<ul>
<li>Sol-Gel to receive $16 million during 2025</li>
<li>Cash runway is expected to extend into the first quarter of 2027; Company expects to have sufficient cash to complete its Phase III clinical trial</li>
<li>SGT-610 Phase III clinical trial top-line results are expected in the fourth quarter of 2026; a significant milestone in the clinical trial of recruiting more than 80% of the patients has been achieved</li>
<li>Sol-Gel now estimates the U.S. market potential for SGT-610 to be between $400 to $500 million annually</li>
<li>SGT-210 Phase 1b trial in Darier patients is ongoing; 50% of the patients have already completed the trial</li>
</ul>
NESS ZIONA, Israel, April 17, 2025 (GLOBE NEWSWIRE) -- Sol-Gel Technologies, Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SLGL#NASDAQ">SLGL</a>), a clinical-stage dermatology company, today announced it has entered into a product purchase agreement with a subsidiary of Mayne Pharma Group Limited (ASX: MYX) (Mayne Pharma) for the sale and exclusive license of the U.S. rights to EPSOLAY and TWYNEO. Under the terms of the agreement, Sol-Gel will receive a total of $16 million in two installments: $10 million in the second quarter of 2025 and $6 million in the fourth quarter of 2025, which is expected to extend the Company's cash runway into the first quarter of 2027. This agreement was executed following the mutual termination by Sol-Gel and Galderma of the exclusive five-year license agreement in the U.S. for both products.

SLGL

Sol-Gel Announces Product Purchase Agreement With Mayne Pharma's Unit For Sale And Exclusive License Of U.S. Rights To EPSOLAY and TWYNEO; Sol-Gel to Receive $16M During 2025

Jefferies analyst Matthew Taylor maintains Abbott Laboratories (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABT#NYSE">ABT</a>) with a Hold and raises the price target from $135 to $137.

Jefferies Maintains Hold on Abbott Laboratories, Raises Price Target to $137

Press Releases

"Game-Changers to Watch CRDL, RMSG, WORX, PET and more…Innovative Companies inside"

Thanksgiving Week Oversold Stocks to Watch: CRDL, QBTS, PRSO, RGTI & More!

"Market Movers: CTOR, CTNT, PNPN.V, KITT, SHIM – More Stocks Inside to Watch"

"Cardiol Therapeutics (NASDAQ: CRDL) Heart Health Innovation – AVCO, GXAI, UPC, and More Stocks Driving Groundbreaking Advances"

PRISM MarketView Features Q&A with President and CEO David Elsley: Cardiol Therapeutics Enters Phase 3 Clinical Trial for CardiolRx™ Addressing Patients with Recurrent Pericarditis

Cardiol Therapeutics to Present at Oppenheimer 35th Annual Healthcare Life Sciences Conference

Cardiol Therapeutics Announces Publication of Research in the Journal of the American College of Cardiology: Basic to Translational Science That Supports Development of Its Proprietary Subcutaneous Drug Candidate, CRD-38, for the Treatment of Heart Failure

Comments

Cardiol Therapeutics

Cardiol Therapeutics (CRDL) Opciones

Cardiol Therapeutics (NASDAQ:CRDL) Bolsa, Cadena de Opciones

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL